← FDA DRUG APPROVALS

FDA ANDA · ANDA087768

BILIVIST

Sponsor: BAYER HLTHCARE

APPLICATION
ANDA087768
TYPE
ANDA
ORIGINAL APPROVAL
1982-08-11
LATEST ACTION
1995-12-28
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

BILIVISTDiscontinued
IPODATE SODIUM 500MG · CAPSULE · ORAL

Approval history

1995-12-28Labeling · Supplement 5AP
1982-08-11OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →